1. Field of the Invention
The present invention is generally related to the use of nanostructures as carriers for molecules. More particularly, the present invention can be used on implant surfaces to retain and release drugs, biomarkers and/or biomolecules on command by an external stimulus.
2. Description of the Prior Art
Nanopores are known in the art for the purpose of sensing macromolecules. They have been applied as stochastic sensors for biological molecules, and can identify and quantify analytes based on nanopore current conductance. For example, biomolecules are electrophoretically driven to a nanopore which is effective in determining the concentration and size distribution of particles. Nanopores can be prepared using different types of technologies such as, but not limited to, organic membrane proteins or by synthetic methods. The advantage of the latter is that the pore size can be tailored.
Techniques known in the art to produce synthetic nanopores include, but are not limited to, ion beam sculpting, micromolding, latent track etching, electron beam based technologies, chemical etching of alloys, semiconductor surfaces, or ceramic compounds and nanotubes. Such nanotubes can be silicon based, carbon based, and metal oxide based. Carbon nanotubes can be produced on catalyst particles using plasma enhanced chemical vapor deposition or plasma spraying techniques. Once a carbon nanotube array is created, it can itself function as a template to form metal oxide nanotubes and nanofibers. To achieve this, a metal can be deposited over the carbon nanotube, followed by subsequent oxidation to form a metal oxide, and finally removal of the carbon tube template by a burning process, leading to the production of hollow metal oxide nanofibers.
Biomaterial implant devices are also known in the art and are frequently used in applications relating to artificial hips, elbows, knees, pacemakers, intraocular lenses, heart valves, and coronary stents. In the United States close to 500,000 patients have hip or knee replacements each year. The material used for such implants are bone grafts, metals, polymers, ceramics and composites. Composites consist mostly of bioinert material with a bioactive material such as hydroxyapatite or bioglass. The standard for long term implantation success of bone implants is a complete osseointegration. Orthopedic and dental implants are commonly coated with titanium oxide coatings because of its excellent biocompatibility and superior mechanical properties. It is known that an implant surface coated with nanostructured features, such as carbon nanotubes, improve bone cell growth. Particularly, an electrochemical anodic oxidation of titanium or aluminum leads to improved characteristics. Such anodization processes can be adjusted to produce nanoscale tubular structures of titanium oxide. Calcium phosphates such as hydroxyapatite, which are the main inorganic component of bone, have particle sizes of 20-40 nanometer, and integrate well with such nanostructured titanium oxide having features in the order of 40 to 100 nanometers.
Another area commonly known for their use of implant devices is in the field of cardiology. In cardiology, stents are placed into coronary arteries that may have narrowed or been blocked by heart disease. Often, such stents are coated with immunosuppressive and antiproliferative drugs that are slowly released into the arteries' bloodstream. Such procedures of stent placement are performed nearly 1,000,000 times annually, with a mean cost of $44,000 per procedure, including around $3,000 for the stent itself (2005 data, American Heart Association). Generally, in the case of drug-eluting stents, a polymer coating is used as a drug reservoir and drug delivery regulating layer. Such drug eluting stents coated with, for instance paclitaxel or sirolimus, reduce the rate of restenosis and prevents the need for repeat procedures in patients with coronary artery disease. However, several recurrent problems are present with the current uses of such polymer coatings in stents, as well as other polymer based implants, such as inflammatory reactions, the need for a common solvent for drugs and polymers, polymer fracture during expansion, and delayed endothelium growth. Currently, certain stents use a titanium oxide layer or other ceramic layer for drug elution.
Other medical applications of the present invention include a number of organ implants/transplants with a nanostructured retention and release surface either in, at the surface of, or nearby the implant. It is also contemplated that the present invention has applications in the field of nanofiltration, nanosieves, and other filtrations using hybrid organic-inorganic, nanoporous materials, for solvent drying or use as a molecular sieve, where the control of opening and closing the nanostructures may be useful to adjust filter properties on demand. In this case, the nanostructures will not need a molecular payload, but the invention will merely trigger the open or closed state of the pore system.
Currently available drug eluting coatings such as polymers and nanostructure surfaces are used in a way that does not allow for precise active control of drug release, but merely releases the drug from the moment of incorporation into the body over a period of time depending on the type of surface, the structure of the surface, the concentrations of reagent used, and other properties. Consequently, there is a need for controlled retention and release of molecules from coatings of stents, as well as bone replacements for joints, dental implants or other implants, in order to provide safe and effective treatments for implant patients. The present invention provides a nanosurface or nanostructure, capable of being used with implants, in order to actively control the retention and/or release of molecules by an external stimulus, such as a radio-frequency field, magnetic field, electric field, infrared/thermal or other electromagnetic field in order to provide customized drug treatments and therapies to patients. The present invention is provided to overcome limitations and drawbacks of the prior art and to provide novel aspects not heretofore available.
The present invention is directed to an apparatus and method of releasing molecules in a controlled manner into tissue surrounding the site of an implant material in a body. The present invention provides for retention and release of drugs, biomarkers and/or biomolecules on command directly from a biocompatible nanosurface by modifying the nanostructures used on the outer layer of the implant.
One aspect of the present invention provides a nanosurface having at least one nanostructure that is capable of retaining and releasing a molecule based on an external stimulus.
Another aspect of the present invention provides an apparatus for releasing molecules directly from an implant. The apparatus comprises an implant having at least one nanostructure for facilitating the retention and release of a molecule based on an external stimulus.
In yet another aspect of the present invention, the apparatus has a first surface and a second surface. The first surface is an implant. The second surface is contiguous to the first surface and covers a portion of the implant. The second surface has at least one nanostructure for facilitating the retention or release of a biomolecule based on an external stimulus.
These and other aspects of the present invention will become apparent to those skilled in the art after a reading of the following description of the preferred embodiment when considered with the drawings, as they support the claimed invention.
The present invention is capable of embodiments in many different forms. Preferred embodiments of the invention are disclosed with the understanding that the present disclosure is to be considered as exemplifications of the principles of the invention and are not intended to limit the broad aspects of the invention to the embodiments illustrated.
The present invention is directed to an apparatus and method of retaining and releasing molecules in a controlled manner into tissue surrounding the site of an implant in a body. Current implants are limited to drug release from a surface immediately after implantation in the body. Such known releases are performed passively using drugs embedded in polymer layers or drugs embedded in the top layer of the implants, such as titanium oxide or hydroxyapatite nanostructures. The present invention allows for active retention and release of molecules on command directly from a biocompatible nanosurface by modification of the nanostructures used within the implant or on an outer surface of the implant. The present invention further provides for delayed or slow release of such molecules by varying release rates of the nanostructures in different areas of the release apparatus.
The present invention is directed to using nanosurfaces or nanostructures with implants such as, but not limited to, joint implants, dental implants, stents or vascular implants. The implant is generally constructed from, but is not limited to, stainless steel, carbon, titanium oxide, hydroxyapatite, metal oxides or ceramic materials. As shown in
The present invention provides for nanostructures that retain and release molecules based on an external stimulus. These nanostructures are located either directly in the implant or in another surface, such as a nanosurface, covering a portion of the implant material. The nanostructures can consist of various configurations capable of retaining and releasing molecules including, but not limited to, nanopores, nanowells, nanotubes or nanocones. The nanostructure may be made of silicon or other semiconductors, carbon, metal oxides such as titanium or aluminum oxide, stainless steel or ceramic materials. The nanostructures are constructed in the nanoporous surface using techniques known in the art such as lithography, ion beam sculpting, micromolding, latent track etching, electron beam based technologies, chemical etching of alloys, semiconductor surfaces, or ceramic compounds and nanotubes.
As shown in
The nanosurface can be loaded with molecules, such as but not limited to drugs, biomarkers, biomolecules, proteins, polymers, peptide and/or polysaccharides. More specifically, one polysaccharide that can be used with the present invention is inulin, a prebiotic having a beneficial effect on bone metabolism and bone health, by enhancing calcium absorption and bone density. Additionally various drugs may be used including, but not limited to, pro-healing drugs such as dexamethasone, anti-proliferation drugs such as paclitaxel and sirolimus, immunosuppressant drugs or any combination of these drugs may be used with the present invention.
As described above, in one embodiment of the present invention bone growth stimulating drugs may be incorporated in hydroxyapatite coatings on top of a titanium oxide surface. Similarly, nanoporous or nanofibrous titanium oxide structures can be used as drug reservoirs that slowly release a drug into the tissue surrounding the implant. This may be achieved by dissolving the drug or biomarker of interest in a solvent and allowing the nanoporous titanium oxide film to soak up the dissolved biomarker. These nanostructured films can be produced by mixing a titanium chloride precursor with a block copolymer, applying it to a surface, and subsequently aging at high temperatures and calcinations.
As discussed above, the nanostructures may be employed to guide the biomolecules and molecular compounds stored inside the nanosurface or underneath the nanosurface. As shown in
Alternative embodiments of the present invention employ magnetic nano- or micrometer sized particles that are linked to the nanostructure mouth edges by a chemical linker, as illustrated in
In an alternative embodiment, the nanostructures are closed by binding or incorporating a larger particle, polymer, biomolecule or protein to the nanopore/nanofiber/nanowell opening, as shown in
In another embodiment, as shown in
In another embodiment, the invention will allow for loading of multiple drugs, biomarkers, polysaccharides, peptides and other molecular compounds onto a stent (cardiac stent, or other stent or other implant device), and release the molecular compounds: sequentially in a time-controlled manner, one-by-one on demand, as a combined release of two or more compounds simultaneously, simultaneously or subsequently at different release rates. This is achieved by triggering only a select area of capped nanostructures to open by designing different regions of capped nanopore structures that respond to different trigger signals, such as but not limited to magnetic fields of different strengths, and/or by created bottleneck caps on the pores that allow for different release rates from different areas on the device.
Certain modifications and improvements will occur to those skilled in the art upon a reading of the foregoing description. The above-mentioned examples are provided to serve the purpose of clarifying the aspects of the invention and it will be apparent to one skilled in the art that they do not serve to limit the scope of the invention. All modifications and improvements have been deleted herein for the sake of conciseness and readability but are properly within the scope of the following claims.
This application claims priority to U.S. Provisional Patent Application Ser. No. 61/069,281 filed Mar. 13, 2008 and U.S. Provisional Patent Application Ser. No. 61/131,795 filed Jun. 12, 2008, the entire disclosures of which are incorporated herein by reference. Priority to this application is claimed under 35 U.S.C. §§119 and/or 120.
Number | Date | Country | |
---|---|---|---|
61069281 | Mar 2008 | US | |
61131795 | Jun 2008 | US |